Physiomics PLC 4th Large Pharma Customer for Virtual Tumour (8746B)
October 12 2015 - 2:00AM
UK Regulatory
TIDMPYC
RNS Number : 8746B
Physiomics PLC
12 October 2015
Physiomics plc
("Physiomics" or "the Company")
4th Large Pharma Customer for Virtual Tumour
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology
company, is pleased to announce that it has signed a new Virtual
Tumour deal with a new pharmaceutical company, the 4(th) large
pharma customer for this service.
The project will be performed on a fee-for-service basis.
Dr Mark Chadwick, CEO of Physiomics, commented:
"It is very pleasing that we have further extended the number of
large pharmas starting to use Virtual Tumour. We look forward to
adding more such customers as the benefits of our model are more
widely understood."
Enquiries:
Physiomics plc
Dr Mark Chadwick, CEO
+44 (0)1865 784 980
WH Ireland Limited
Katy Mitchell
+44 (0) 161 832 2174
About Physiomics plc
Physiomics (AIM:PYC) is a computational systems biology services
company applying simulations of cell behaviour to drug development
to reduce the high attrition rates of clinical trials. 80-90 per
cent of all clinical drug candidates fail to reach the market and
estimates show that an overall ten per cent improvement in success
rates could reduce the cost of one drug's development by as much as
$242 million, from the current estimate of around $800 million(1)
.
Physiomics develops computational systems biology models to
predict and understand cancer drug efficacy from pre-clinical
research to clinical development. Physiomics has created detailed
mathematical models incorporating the most important molecular
events taking place during the human cell cycle and apoptosis
processes. The company's SystemCell(R) technology enables the
simulation of populations of "virtual cells". The company has also
developed a "Virtual Tumour" model to simulate the effect of
anti-cancer drugs on tumour growth. The models are used to optimise
compound design and to design drug schedules and combination
therapies.
Physiomics, based in Oxford, UK, was founded in 2001, and
floated on AIM in 2004. For further information, please visit
www.physiomics-plc.com
SystemCell(R) is a registered trademark of Physiomics plc
(1) Tufts Centre Impact Report 2002
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRUGGGUUUPAGQB
(END) Dow Jones Newswires
October 12, 2015 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2023 to Apr 2024